[Form 4] Solid Biosciences Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jessie Hanrahan, identified as a Director and the company's Chief Regulatory Officer, acquired equity in Solid Biosciences Inc. (SLDB) on 08/14/2025. The filing reports an employee stock option to purchase 142,500 shares at a $6.17 exercise price and 71,250 restricted stock units (RSUs), each RSU representing a right to one share. Following the transactions Hanrahan beneficially owns 142,500 options and 71,250 RSUs. The awards were granted on the stated date and include vesting terms: 50% of the original RSU grant vests on the second anniversary of the grant date and 25% annually thereafter until the fourth anniversary. The form is signed by an attorney-in-fact on 08/18/2025.

Positive

• Material equity grant disclosed: Reporting person received 142,500 options and 71,250 RSUs, aligning executive incentives with shareholders
• Clear vesting schedule provided: RSUs vest 50% on the second anniversary and 25% annually thereafter, showing retention structure

Negative

• None.

Insights

Compensation Analyst

TL;DR: Large equity awards were granted to a senior officer with multi-year vesting, indicating retention-focused compensation.

The awards to the Chief Regulatory Officer consist of a sizable stock option and RSU package totaling 213,750 equity instruments (142,500 options plus 71,250 RSUs). The RSU vesting schedule is explicitly retention-oriented: half vests on the second anniversary and the remainder vests over the next two years. The option exercise price of $6.17 is disclosed, and the option term extends through the expiration date shown. These elements are consistent with standard executive long-term incentive design to align management with shareholder value over multiple years. This filing appears to be a routine grant rather than a change-in-control or special one-time award.

Securities/Compliance Analyst

TL;DR: Form 4 reports an insider acquisition of equity on 08/14/2025, properly disclosed and signed by attorney-in-fact.

The Form 4 shows acquisition transactions coded A for both an employee stock option (142,500 shares at $6.17) and restricted stock units (71,250 RSUs). Beneficial ownership amounts after the transaction are explicitly reported. The filing includes the reporting person’s relationship to the issuer and a signature date of 08/18/2025, satisfying basic Section 16 disclosure requirements. There are no corrective amendments or additional transactions reported. Based solely on the filing text, this is a standard, timely insider equity grant disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanrahan Jessie

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.17	08/14/2025		A		142,500		(1)	08/14/2035	Common Stock	142,500	$0.00	142,500	D
Restricted Stock Units	(2)	08/14/2025		A		71,250		(1)	(1)	Common Stock	71,250	$0.00	71,250	D

Explanation of Responses:

1. The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

	/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jessie Hanrahan acquire according to the Form 4 for SLDB?

The filing shows acquisition of an employee stock option for 142,500 shares at an exercise price of $6.17 and 71,250 restricted stock units (RSUs).

When were the transactions reported on the SLDB Form 4?

The transactions are dated 08/14/2025 and the Form 4 is signed on 08/18/2025.

What vesting terms are disclosed for the RSUs in the Form 4?

The RSUs vest over four years: 50% of the original number vests on the second anniversary of the grant date and 25% annually thereafter until the fourth anniversary.

What is Jessie Hanrahan’s role at Solid Biosciences according to the filing?

The Form 4 lists Jessie Hanrahan as a Director and Officer, specifically the Chief Regulatory Officer.

How many shares does Hanrahan beneficially own following the reported transactions?

Following the reported transactions Hanrahan beneficially owns 142,500 options and 71,250 RSUs.